S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
NASDAQ:BCPC

Balchem (BCPC) Stock Price, News & Analysis

$155.17
+0.71 (+0.46%)
(As of 09:45 AM ET)
Today's Range
$154.89
$155.17
50-Day Range
$139.37
$157.27
52-Week Range
$110.74
$159.52
Volume
2,015 shs
Average Volume
108,961 shs
Market Capitalization
$5.01 billion
P/E Ratio
46.32
Dividend Yield
0.51%
Price Target
$135.00

Balchem MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
12.6% Downside
$135.00 Price Target
Short Interest
Healthy
1.12% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.54
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$11.84 M Sold Last Quarter
Proj. Earnings Growth
12.08%
From $4.14 to $4.64 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.32 out of 5 stars

Basic Materials Sector

40th out of 170 stocks

Chemicals & Allied Products Industry

3rd out of 13 stocks

BCPC stock logo

About Balchem Stock (NASDAQ:BCPC)

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.

BCPC Stock Price History

BCPC Stock News Headlines

BCPC Apr 2024 165.000 call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Balchem: Potential Turnaround Is In The Price
BCPC Mar 2024 150.000 call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Balchem Full Year 2023 Earnings: EPS Misses Expectations
BCPC Mar 2024 175.000 call
BCPC Mar 2024 145.000 call
Balchem Q4 2023 Earnings Preview
Balchem Corp BCPC
See More Headlines
Receive BCPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Balchem and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/19 Dividend
12/26/2023
Ex-Dividend for 1/16 Dividend
12/28/2023
Dividend Payable
1/16/2024
Dividend Payable
1/19/2024
Last Earnings
2/16/2024
Today
3/28/2024
Next Earnings (Estimated)
4/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Chemicals & allied products
Sub-Industry
Specialty Chemicals
Current Symbol
NASDAQ:BCPC
CUSIP
05766520
CIK
9326
Employees
1,302
Year Founded
1967

Price Target and Rating

Average Stock Price Target
$135.00
High Stock Price Target
$135.00
Low Stock Price Target
$135.00
Potential Upside/Downside
-12.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$108.54 million
Pretax Margin
14.88%

Debt

Sales & Book Value

Annual Sales
$922.44 million
Cash Flow
$5.10 per share
Book Value
$32.69 per share

Miscellaneous

Free Float
31,696,000
Market Cap
$4.98 billion
Optionable
Optionable
Beta
0.71

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Theodore L. Harris (Age 59)
    Chairman, CEO & President
    Comp: $2.33M
  • Mr. Carl Martin Bengtsson (Age 46)
    Executive VP, CFO & Treasurer
    Comp: $864.13k
  • Ms. Hatsuki Miyata (Age 48)
    Executive VP, General Counsel & Secretary
    Comp: $618.21k
  • Mr. Jonathan H. Griffin (Age 48)
    Senior VP and GM of Animal Nutrition & Health
    Comp: $624.01k
  • Mr. Martin Luther Reid (Age 56)
    Senior VP & Chief Supply Chain Officer
    Comp: $672.26k
  • Mr. William A. Backus CPA (Age 58)
    VP & Chief Accounting Officer
    Comp: $560.79k
  • Mr. Michael R. Sestrick Ph.D. (Age 60)
    Senior VP & CTO
  • Mr. M. Brent Tignor (Age 45)
    Senior VP & Chief Human Resources Officer
  • Mr. Frederic Boned (Age 46)
    Senior VP and GM of Human Nutrition & Health
  • Mr. Job L. van Gunsteren (Age 48)
    Senior VP & GM of Specialty Products

BCPC Stock Analysis - Frequently Asked Questions

Should I buy or sell Balchem stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Balchem in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCPC shares.
View BCPC analyst ratings
or view top-rated stocks.

What is Balchem's stock price target for 2024?

1 brokerages have issued 1-year price objectives for Balchem's stock. Their BCPC share price targets range from $135.00 to $135.00. On average, they anticipate the company's share price to reach $135.00 in the next year. This suggests that the stock has a possible downside of 12.6%.
View analysts price targets for BCPC
or view top-rated stocks among Wall Street analysts.

How have BCPC shares performed in 2024?

Balchem's stock was trading at $148.75 at the beginning of 2024. Since then, BCPC stock has increased by 3.8% and is now trading at $154.46.
View the best growth stocks for 2024 here
.

When is Balchem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our BCPC earnings forecast
.

How were Balchem's earnings last quarter?

Balchem Co. (NASDAQ:BCPC) issued its quarterly earnings results on Friday, February, 16th. The basic materials company reported $0.95 earnings per share for the quarter, topping analysts' consensus estimates of $0.93 by $0.02. The basic materials company had revenue of $228.70 million for the quarter, compared to the consensus estimate of $234.66 million. Balchem had a net margin of 11.77% and a trailing twelve-month return on equity of 10.69%. The firm's revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.66 earnings per share.

How often does Balchem pay dividends? What is the dividend yield for Balchem?

Balchem announced an annual dividend on Monday, December 4th. Stockholders of record on Wednesday, December 27th will be given a dividend of $0.79 per share on Friday, January 19th. This represents a yield of 0.6%. The ex-dividend date of this dividend is Tuesday, December 26th. This is a boost from the stock's previous annual dividend of $0.40.
Read our dividend analysis for BCPC
.

Is Balchem a good dividend stock?

Balchem (NASDAQ:BCPC) pays an annual dividend of $0.79 per share and currently has a dividend yield of 0.51%. The company has been increasing its dividend for 15 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 23.58%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BCPC will have a dividend payout ratio of 17.03% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BCPC.

What is Dino A. Rossi's approval rating as Balchem's CEO?

25 employees have rated Balchem Chief Executive Officer Dino A. Rossi on Glassdoor.com. Dino A. Rossi has an approval rating of 85% among the company's employees. 62.0% of employees surveyed would recommend working at Balchem to a friend.

What other stocks do shareholders of Balchem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Balchem investors own include Ecolab (ECL), CVS Health (CVS), AbbVie (ABBV), Johnson & Johnson (JNJ), Lowe's Companies (LOW), Altria Group (MO), NVIDIA (NVDA), AT&T (T), Analog Devices (ADI) and Bristol-Myers Squibb (BMY).

Who are Balchem's major shareholders?

Balchem's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.76%), Vanguard Group Inc. (11.75%), Wasatch Advisors LP (5.93%), Conestoga Capital Advisors LLC (3.36%), Geneva Capital Management LLC (2.38%) and Dimensional Fund Advisors LP (2.13%). Insiders that own company stock include David B Fischer, Gunsteren Job Leonard Van, Michael Robert Sestrick, Theodore L Harris and William A Backus.
View institutional ownership trends
.

How do I buy shares of Balchem?

Shares of BCPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Balchem have any subsidiaries?
The following companies are subsidiares of Balchem: Aberco Inc., Aberco Inc., Albion Laboratories Inc., Albion Laboratories Inc., BCP Ingredients Inc., Balchem BV, Balchem Italia Srl, Balchem Ltd., Balchem NV, Balchem Pte Ltd., Balchem Pty Ltd., Balchem Sdn Bhd, Bioscreen technologies, Chemogas Holding NV, Chol-Mix Kft, Innovative Food Processors, SensoryEffects, SensoryEffects Cereal Systems Inc., SensoryEffects Inc., Stereo Gas Philippines Inc., and Zumbro River Brand Inc..
Read More
This page (NASDAQ:BCPC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners